Navigation Links
Study Finds That Migraine Drug Can Ease The Severest Of Facial Pain

A new study in Japan has found migraine medication sumatriptan, known by the brand names Imitrex or Imigran, can provide relief for pain// due to trigeminal neuralgia up to eight hours.

Now researchers have found that a migraine medication could provide relief for people who suffer from, trigeminal neuralgia. Researchers had injected the drug and found it produced rapid and significant pain relief without serious adverse reactions.

Pain experienced with trigeminal neuralgia that affects the nerves in the face, sometimes known as tic douloureux, comes in lightning-like stabs that radiate from the angle of the jaw to the front of the face. The shocks are momentary but can repeat for several seconds. Paroxysms may last for hours, and then subside for long periods. This pain is often considered as one of the severest pains. Compression of the root of the trigeminal nerves by an artery is thought to cause trigeminal neuralgia.

Dr Akifumi Kanai and colleagues from Kitasato University School of Medicine explained this in the journal of Headache. The team led by Dr Kanai's examined the possible effectiveness of a subcutaneous injection of sumatriptan compared with saline in the treatment of trigeminal neuralgia in 24 patients. According to investigators, it was found to significantly decrease pain scores on a 0-10 scale from 8.3 to 2.4, according to the investigators. Pain scores did not change with placebo injection. Twenty patients described their pain as moderately or slightly better after sumatriptan treatment as compared with only one patient after being injected with saline injection. The analgesic effect of sumatriptan lasted for 1 to 20 hours, averaging 7.9 hours overall.

Dr Julio Pascual of University Hospital in Salamanca, Spain, in his editorial explained that the rapid onset of relief is plus, but subcutaneous injections that should be given at least twice a day would be a drawback. He went to suggest that sumatrip tan might be ideal as short-term treatment until oral drugs begin to work, or as rescue treatment. He also stated that he would like to see if other "triptans" that can be delivered orally or by nasal spray would work for trigeminal neuralgia.


'"/>




Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/24/2017)... ... 2017 , ... Come to PAINWeekEnd (PWE) Tampa on May 20 and 21, ... and exciting 2-day program. , An attendee at a recent PAINWeekEnd said, "Very ... about the course entitled Ain't Misbehavin': Decreasing and Managing Pain Patient Aberrant Behavior, presented ...
(Date:4/24/2017)... ... April 24, 2017 , ... “Learning to Use Your SPIRITUAL ... “Learning to Use Your SPIRITUAL COMPASS To Navigate Life Issues” is the creation ... former Chairman of the Board of Directors for CONTACT USA, and former member of ...
(Date:4/24/2017)... Spain (PRWEB) , ... April 24, 2017 , ... ... on the development of next generation neuro-thrombectomy systems for the treatment of Acute ... and manufacture its ANCD BRAIN device as the product advances towards regulatory and ...
(Date:4/22/2017)... ... April 22, 2017 , ... ... has named PROSHRED® Security of Philadelphia its “Woman-Owned Small Business of ... specializes in providing information destruction , recycling, and compliance services to ...
(Date:4/21/2017)... ... April 21, 2017 , ... Providing broad access to life-saving drugs ... there is a better way to address this problem. , That was the message ... Policy and Economics at the University of Southern California, who served as the keynote ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017 Research and Markets has announced the ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ... ... will rise from USD 20 Billion in 2015 to around USD ... Technologies - Innovation Driven by Rapidly Expanding Injectables Market and Increasing ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
Breaking Medicine Technology: